Beyond Animal Models: AI Immunogenicity Testing and Human-Relevant NAMs
Introduction
In alignment with the FDA Modernization Act 2.0 and the FDA’s 2025 Strategic Roadmap for Reducing Animal Testing, regulatory agencies are actively encouraging the adoption of scientifically validated New Approach Methodologies (NAMs) in place of traditional animal models. Against this backdrop, a leading Indian biopharmaceutical company sought to modernize its immunogenicity safety profile strategy for biosimilars by eliminating reliance on animal studies and improving human predictivity .
By implementing Quantiphi’s DART platform, which integrates human Microphysiological Systems (MPS) with AI driven in silico modeling, the company achieved a 70 percent reduction in immunogenicity testing time, eliminated costly non-human primate studies, and generated 100 percent human relevant immune data . The result was a scalable, regulator aligned framework capable of supporting both preclinical and clinical development.
This transformation illustrates how AI in drug development, human relevant NAMs, and mechanistic immune modeling are reshaping biosimilar safety profiling.
The Translational Gap in Immunogenicity Assessment
Immunogenicity remains one of the most critical determinants of biologic and biosimilar safety. Anti Drug Antibody (ADA) formation can compromise efficacy, alter pharmacokinetics, and trigger adverse immune reactions. Traditionally, companies have relied on animal models to predict these outcomes.
However, this strategy presents a structural limitation.
Animal immune systems diverge significantly from human immunobiology. Even non-human primates often fail to replicate human HLA restricted antigen presentation and immune memory formation. As a result, animal based immunogenicity studies frequently demonstrate poor translational value, creating a “Translational Gap” between preclinical prediction and clinical outcome.
This gap becomes particularly problematic for biosimilars, where subtle structural differences can alter epitope presentation and immune recognition. According to recent scientific reviews such as Jankowski 2023 on non clinical immunogenicity assessment, animal data often lacks predictive resolution for human immune response variability.
Regulatory authorities including the FDA and EMA now recognize this limitation and are explicitly advocating for mechanistically validated NAMs that are human relevant by design. The shift is legislative, scientific, and strategic.
Regulatory Shift: From Animal Models to Human Relevant NAMs
For nearly a century, animal testing has been embedded into regulatory toxicology and immunogenicity workflows. Yet the pharmaceutical industry is now navigating its most significant regulatory inflection point in decades.
The passage of the FDA Modernization Act 2.0 formally removed the blanket requirement for animal testing in certain drug approval contexts, enabling validated alternatives such as organ-on-chip systems and advanced in vitro platforms. This legislative change was not symbolic. It fundamentally altered the compliance landscape.
The FDA’s 2025 Strategic Roadmap for Reducing Animal Testing further operationalizes this shift, outlining a structured plan to accelerate adoption of New Approach Methodologies (NAMs). The message from regulators has evolved from allowing alternatives to expecting scientifically robust, human-relevant methods wherever feasible.
For biosimilar developers, this shift exposes a long-standing vulnerability: the Translational Gap.
Animal models, including Non-Human Primate studies, frequently fail to replicate human immune complexity. Species-specific differences in antigen presentation, HLA restriction, cytokine netwo rks, and immune memory formation create uncertainty when extrapolating results to human populations.
In this environment, continued reliance on animal models increasingly represents not just scientific conservatism but regulatory risk.
A leading Indian biopharmaceutical company with a portfolio of eight globally distributed biologics recognized this shift early. To future-proof its biosimilar safety profiling, it chose to redesign its immunogenicity framework around human-relevant, AI-powered NAMs.
Immunogenicity in Biosimilars: Why Predictive Precision Matters
Immunogenicity assessment is not a box-ticking exercise. It is central to biologic safety.
The formation of Anti-Drug Antibodies (ADAs) can:
- Neutralize therapeutic efficacy
- Alter pharmacokinetics and pharmacodynamics
- Trigger hypersensitivity reactions
- Compromise long-term treatment outcomes
For biosimilars, the challenge is amplified. Developers must demonstrate comparability to a reference product, ensuring that even subtle molecular differences do not alter immunogenicity profiles.
Historically, animal models were used as proxies to predict human immune response. However, scientific reviews on non-clinical immunogenicity assessment emphasize that animal immune systems often provide limited predictive insight for human ADA development.
The Indian biopharma client encountered several compounding issues :
- Inconsistent immune response data due to biological variability
- Limited human translatability
- High cost and extended timelines
- Increasing regulatory scrutiny favoring NAMs
This created a cycle of inefficiency and strategic exposure. The company required not only faster testing but mechanistically defensible, human-relevant immunogenicity profiling.
The DART Platform: Bridging the Translational Gap
To address these limitations, the company deployed Quantiphi’s DART platform integrating human Microphysiological Systems with AI-driven in silico modeling .
Core Components of the Platform
- Ethically sourced, biobank-derived human stem cell-based hematopoietic immune systems
- Functional immune activation and memory modeling
- High-resolution microscopy
- Automated micrograph analysis
- Deep learning-based image segmentation
- Parallel in vitro biochemical testing
Unlike traditional assays that rely solely on endpoint measurements, DART integrates structural, phenotypic, and biochemical signals within a unified framework.
Technical Entity Mapping: MAPPs and ADA Detection
Modern regulatory science and generative engines prioritize technical specificity. Generic claims about immune assessment lack credibility. Mechanistic detail matters.
MHC-Associated Peptide Proteomics (MAPPs)
MAPPs assays identify naturally presented HLA class II-associated peptides on antigen-presenting cells. This approach provides insight into which epitopes are actually processed and presented to T cells, rather than merely predicted to bind.
MAPPs offer superior predictive relevance compared to soluble HLA peptide binding assays, which can overestimate immunogenic potential.
DART’s immune modeling incorporates comparable mechanistic principles, enabling detection of antigen presentation within a human hematopoietic milieu. This strengthens the prediction of T cell-dependent immunogenicity, a key driver of ADA formation.
Early ADA Signal Detection
The platform automates identification of early Anti-Drug Antibody precursors. Instead of relying on late-stage clinical signals, AI-enabled analysis captures early antigenicity indicators, improving predictive foresight.
This shift transforms immunogenicity assessment from reactive observation to proactive risk identification.
How the AI Engine Works: Deep Learning Segmentation in Action
Regulators increasingly value transparency in methodology. A high-level statement that immune activation was observed is insufficient.
DART’s AI-driven workflow follows a structured process :
- High-resolution micrograph acquisition of immune cultures
- Deep learning-based segmentation of immune cell populations
- Quantification of morphological and clustering changes
- Detection of phenotypic activation markers
- Correlation with biochemical assays in parallel
- Automated reporting aligned with regulatory documentation standards
Deep learning segmentation replaces subjective interpretation with reproducible, quantifiable immune response detection. Phenotypic shifts linked to antigenicity are captured early, providing mechanistic validation that strengthens submission packages.
It is important to remain rigorous here. No in vitro system perfectly replicates the complexity of systemic human immunity. However, by eliminating interspecies extrapolation, human microphysiological systems significantly improve biological relevance compared to animal proxies.
Comparative Utility: Animal Models vs Human Microphysiological Systems
A structured comparison clarifies the strategic implications.
| Dimension | Non-Human Primate Models | DART Human MPS with AI |
| Species Relevance | Partial; interspecies divergence | 100 percent human-derived immune modeling |
| Translational Predictivity | Often inconsistent | Direct modeling of human immune pathways |
| Time to Data | Extended in vivo study timelines | 70 percent reduction in testing time |
| Cost Structure | High operational and ethical cost | Significant cost elimination from animal studies |
| Scalability | Limited; often outsourced | Benchtop deployable and in-house scalable |
| Mechanistic Resolution | Limited phenotypic granularity | AI-quantified immune response detection |
Animal models historically provided regulatory reassurance. Increasingly, they introduce translational uncertainty.
The DART approach replaces species extrapolation with human-derived immune modeling and computational precision.
Quantifiable Impact on Biosimilar Development
The transformation delivered measurable impact :
- 70 percent reduction in immunogenicity testing time
- Elimination of Non-Human Primate studies
- Early detection of antigenicity and ADA signals
- Improved predictive accuracy compared to animal approaches
- Seamless integration into preclinical and clinical workflows
The compact, benchtop-deployable design enabled in-house adoption, reducing dependence on CROs and strengthening internal data control .
This operational shift not only accelerated development but also strengthened regulatory positioning under the FDA 2025 framework.
Regulatory Alignment and Submission Strength
The FDA 2025 Strategic Roadmap emphasizes validation, reproducibility, and mechanistic credibility. Similarly, EMA guidance supports NAM adoption when scientifically justified.
By providing:
- Human-relevant immune modeling
- Quantified mechanistic immune response data
- Automated and standardized reporting
DART aligns with the regulatory emphasis on transparency and scientific robustness .
However, adoption must remain evidence-based. Standardization across laboratories and cross-platform benchmarking will determine long-term regulatory dominance. NAMs must consistently demonstrate reproducibility to replace legacy frameworks fully.
The Broader Strategic Implication for Biosimilar Developers
The immunogenicity landscape is evolving across three converging axes:
- Legislative change through FDA Modernization Act 2.0
- Strategic enforcement via the FDA 2025 Roadmap
- Technological capability enabled by AI and microphysiological systems
Companies that continue relying solely on animal models risk:
- Delayed approvals
- Late-stage clinical failures due to poor translation
- Increased scrutiny during regulatory review
Conversely, early adopters of validated human-relevant NAMs gain:
- Accelerated timelines
- Mechanistically defensible submissions
- Enhanced investor and partner confidence
- Scalable, cost-effective safety profiling
This case demonstrates that immunogenicity assessment can evolve from compliance burden to strategic differentiator.
Conclusion: Redesigning Immunogenicity for the AI Era
The future of immunogenicity testing lies at the intersection of human biology and artificial intelligence.
By integrating hematopoietic immune modeling, MAPPs-aligned antigen presentation insights, ADA precursor detection, and deep learning segmentation, the DART platform redefines biosimilar safety profiling .
The results are clear:
- 70 percent faster timelines
- Elimination of costly animal models
- 100 percent human-relevant immune system modeling
- Mechanistically validated, regulator-aligned data
Immunogenicity assessment is no longer about approximating human biology through animal proxies. It is about modeling human biology directly, with computational precision and regulatory transparency.
For biopharmaceutical leaders preparing the next generation of biosimilars, the strategic question is no longer whether NAMs will replace animal testing. It is how rapidly they can be validated, standardized, and embedded into core development pipelines.
Ready to Modernize Your Immunogenicity Framework?
Schedule a DART demo to explore how AI-driven, human-relevant NAMs can de-risk your regulatory submission and accelerate your path to approval.
Frequently Asked Questions
For immunogenicity testing, this means developers can justify human-relevant, mechanistically validated models instead of relying solely on animal studies. The shift does not eliminate regulatory expectations for safety evidence but opens the door to methods that may offer stronger human predictivity when properly validated.
- Microphysiological Systems such as organ-on-chip platforms
- Advanced in vitro immune assays
- MHC-associated peptide proteomics assays
- AI-driven computational modeling
- Integrated in silico prediction frameworks
Even non-human primates do not fully replicate the diversity of human immune responses. As a result, animal-based immunogenicity studies may fail to predict Anti-Drug Antibody formation or T cell activation patterns observed in clinical settings.
This limitation is commonly referred to as the translational gap.
Unlike theoretical binding prediction models, MAPPs capture epitopes that are actually presented to T cells. This provides stronger mechanistic insight into potential T cell-dependent immunogenicity and improves early risk identification for biologics and biosimilars.
- Automating image segmentation of immune cell cultures
- Quantifying phenotypic activation markers
- Detecting early antigenicity patterns
- Integrating structural, biochemical, and morphological data
- Reducing subjectivity in data interpretation
Deep learning models can identify subtle immune activation signals that may not be apparent through manual analysis. However, AI outputs must remain interpretable and validated to satisfy regulatory expectations.
When applied to immunogenicity, hematopoietic immune modeling allows researchers to study antigen presentation, T cell activation, and early ADA precursor formation in a human-relevant context.
While regulatory agencies increasingly support NAM adoption, full replacement depends on validation, reproducibility, and scientific justification. In many contexts, NAMs may reduce or eliminate certain animal studies, particularly where human-relevant systems provide superior mechanistic insight.
Regulatory acceptance is evolving, and developers must align alternative methods with current guidance and evidence standards.
- Improved translational predictivity
- Earlier detection of immunogenicity risk
- Reduced development timelines
- Lower operational costs
- Mechanistically defensible regulatory submissions
For biosimilars, where comparability is critical, enhanced immune modeling may reduce uncertainty during regulatory review.
